Skip to content

analgesic effect of intravenous ketamine

Comparison of analgesic effect of intravenous ketamine versus intravenous Morphine in isolated orthopedic trauma patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015122225660N1
Enrollment
606
Registered
2016-02-28
Start date
2014-05-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Upper or Lower limb fracture. Condition 2: Upper or Lower limb dislocation. Fracture of upper limb, level unspecified, Fracture of lower limb, level unspecified Dislocation, sprain and strain of unspecified joint and ligament of upper limb or lower limb, level unspecified

Interventions

Intervention 1: Intervention1 (case group): In Group A, patients receive a dose of 0.25 mg / kg iv ketamine. Drugs’ dose are calculated based on patient weight. Pain severity base on visual analog sco
Treatment - Drugs
Intervention1 (case group): In Group A, patients receive a dose of 0.25 mg / kg iv ketamine. Drugs’ dose are calculated based on patient weight. Pain severity base on visual analog score (VAS) and com
Intervention2 (case group): In Group B, patients receive a dose of 0.1 mg / kg iv morphine. Drugs’ dose are calculated based on patient weight. Pain severity base on visual analog score (VAS) and comp

Sponsors

Vice chancellor for research,Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with isolated trauma with fracture in the upper or lower extremities; aged between 15 and 55 years old; with Visual Analogue Scale pain score of more than 50 mm. Exclusion criteria: Patient’s refusal to participate in the study; having an underlying medical condition such as migraine, cardiac ischemia, schizophrenia, history of allergy to opiates or ketamine, head trauma or loss of consciousness; blood pressure of more than 180/100; vital signs Instability before and during the study; pregnancy; any inability to express their pain during the study; presence of other trauma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain severity. Timepoint: 0, 5th,10th, 20th minute. Method of measurement: Visual analog scale.

Secondary

MeasureTime frame
Dizziness, nausea, burning throat, amnesia, headache,. Timepoint: Before intervention, 5, 10 and 20 minutes after intervention. Method of measurement: physical examination.;Need for rescue analgesia. Timepoint: 20 minutes after intervention. Method of measurement: Visual analog scale of pain.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Parvizrad

Arak University of Medical Sciences

r.parvizrad@arakmu.ac.ir+98 86 3222 0003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026